Jun 08, 2022 / 01:30PM GMT
Brandon Couillard - Jefferies LLC, Research Division - Equity Analyst
Okay. We'll go ahead and get started. Thanks, everybody, for being here. Good morning. Welcome to the Jefferies 2022 Global Healthcare Conference back in person. It's great to see everybody. I'm Brandon Couillard, I cover the life science tools and diagnostics space. Very happy to have Bio-Techne with us back at the conference this year. And here to share an update with us, CEO, Chuck Kummeth. Chuck?
Charles R. Kummeth - Bio-Techne Corporation - CEO, President & Director
Thank you. Is this working? Can you hear me? Good.
All right. Well, we'll get this started. It's been a while since we have given a presentation actually, so it's good to be back.
All right, good. First, our safe harbor. You guys have all seen these before, but we recommend you go online and look at our reconciliations and see all the real data.
Overview of our company. We're about a $15 billion company as of January to now. Like everybody else, we've come down a fair amount, but not as much as
Bio-Techne Corp at Jefferies Healthcare Conference Transcript
Jun 08, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers